Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results

被引：0
|
作者：
Bardia, A.
Diamond, J. R.
Mayer, I. A.
Isakoff, S. J.
Abramson, V.
Starodub, A. N.
O'Shaughnessy, J.
Kalinsky, K.
Moroose, R.
Shah, N.
Juric, D.
Shapiro, G. I.
Guarino, M.
Ocean, A. J.
Messersmith, W. A.
Berlin, J. D.
Wegener, W. A.
Sharkey, R. M.
Goldenberg, D. M.
Vahdat, L. T.
机构：
[1] Massachusetts Gen Hosp, Harvard Med Sch, Ctr Canc, Boston, MA 02114 USA
[2] Univ Colorado, Ctr Canc, Aurora, CO USA
[3] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[4] Indiana Univ, Hlth Ctr Canc Care, Goshen, IN USA
[5] Texas Oncol Sammons Canc Ctr, Dallas, TX USA
[6] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA
[7] Univ Florida, Hlth Canc Ctr, Orlando, FL USA
[8] Dana Farber Canc Inst, Harvard Med Sch, Boston, MA 02115 USA
[9] Helen F Graham Canc Ctr, Newark, DE USA
[10] Weill Cornell Med, New York, NY USA
[11] Immunomed Inc, Morris Plains, NJ USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P4-22-15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-22-15
引用
收藏
页数：3
相关论文
共 50 条
  • [41] BAT8003, a potent anti-Trop-2 antibody-drug conjugate, for the treatment of triple negative breast cancer
    Tang, W.
    Huang, X.
    Ou, Z.
    Yan, H.
    Gan, J.
    Dong, Q.
    Tan, B.
    Yang, Y.
    Guo, Y.
    Li, S.
    Thomas, B.
    Yu, J-C
    CANCER RESEARCH, 2019, 79 (04)
  • [42] Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
    Bardia, A.
    Messersmith, W. A.
    Kio, E. A.
    Berlin, J. D.
    Vahdat, L.
    Masters, G. A.
    Moroose, R.
    Santin, A. D.
    Kalinsky, K.
    Picozzi, V
    O'Shaughnessy, J.
    Gray, J. E.
    Komiya, T.
    Lang, J. M.
    Chang, J. C.
    Starodub, A.
    Goldenberg, D. M.
    Sharkey, R. M.
    Maliakal, P.
    Hong, Q.
    Wegener, W. A.
    Goswami, T.
    Ocean, A. J.
    ANNALS OF ONCOLOGY, 2021, 32 (06) : 746 - 756
  • [43] Initial results of a new antibody-drug conjugate (ADC), IMMU-130 (labetuzumab-SN38), in patients with metastatic colorectal cancer (mCRC)
    Segal, N. H.
    Verghis, J.
    Govindan, S.
    Maliakal, P.
    Sharkey, R. M.
    Wegener, W. A.
    Goldenberg, D. M.
    Saltz, L. B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S545 - S546
  • [44] Sacituzumab Govitecan as a Second-Line Treatment in Relapsed/Refractory Metastatic Triple-Negative Breast Cancer Patients: A Systematic Review and Meta-analysis
    Kathpalia, Meghavi
    Sharma, Anurag
    Kaur, Navkiran
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (01) : 44 - 53
  • [45] First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
    Starodub, Alexander N.
    Ocean, Allyson J.
    Shah, Manish A.
    Guarino, Michael J.
    Picozzi, Vincent J., Jr.
    Vahdat, Linda T.
    Thomas, Sajeve S.
    Govindan, Serengulam V.
    Maliakal, Pius P.
    Wegener, William A.
    Hamburger, Steven A.
    Sharkey, Robert M.
    Goldenberg, David M.
    CLINICAL CANCER RESEARCH, 2015, 21 (17) : 3870 - 3878
  • [46] Development of Triple-negative breast cancer (TNBC) syngeneic models and TROP2-directed antibody-drug conjugate (ADC) surrogate to model therapeutic combinations
    Chou, Chih-Chien
    Kardos, Jordan
    Yang, Becky
    Orf, Jessica
    Dave, Rutwij
    Lai, Yurong
    Lee, Chingwei V.
    Papalia, Giuseppe A.
    Boyd, Kelli
    Diehl, Lauri
    Scholler, Nathalie
    CANCER RESEARCH, 2023, 83 (05)
  • [47] METRIC: A randomized international phase 2b study of the antibody-drug conjugate (ADC) glembatumumab vedotin (GV) in gpNMB-overexpressing, metastatic, triple-negative breast cancer (mTNBC)
    Vahdat, L. T.
    Forero-Torres, A.
    Schmid, P.
    Blackwell, K.
    Telli, M. L.
    Melisko, M.
    Holgado, E.
    Moebus, V.
    Cortes, J.
    Fehrenbacher, L.
    Montero, A. J.
    Ma, C.
    Nanda, R.
    Wright, G. S.
    He, Y.
    Bagley, R. G.
    Halim, A.
    Turner, C. D.
    Yardley, D. A.
    CANCER RESEARCH, 2019, 79 (04)
  • [48] ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), for the treatment of first-line metastatic triple negative breast cancer (mTNBC).
    Ma, Fei
    Qiu, Fuming
    Tong, Zhongsheng
    Shi, Yehui
    Yu, Guohua
    Wu, Xinhong
    Wang, Hong
    Wang, Jiani
    Yang, Hua
    Liu, Anwen
    Zhang, Yan
    Zheng, Hongmei
    Lan, Qiongyu
    Zhang, Yongqiang
    Cheng, Ying
    Zhou, Qing
    Xing, Xiaoyan
    Chen, Xiaomei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer
    Huang, Wenpeng
    Li, Liming
    Zhou, Yuhan
    Yang, Qi
    Mixdorf, Jason C.
    Barnhart, Todd E.
    Hsu, Jessica C.
    Saladin, Rachel J.
    Liu, Chihao
    Rosenkrans, Zachary T.
    Engle, Jonathan W.
    Gao, Jianbo
    Kang, Lei
    Cai, Weibo
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2025,
  • [50] Safety, efficacy, and pharmacokinetics of a new humanized anti-Trop-2 antibody-SN-38 conjugate (IMMU-132) for the treatment of diverse epithelial cancers: Phase I clinical experience.
    Starodub, Alexander N.
    Ocean, Allyson J.
    Guarino, Michael J.
    Chuang, Ellen
    Shah, Manish A.
    Tagawa, Scott
    Picozzi, Vincent J.
    Thomas, Sajeve S.
    Maliakal, Pius P.
    Wegener, William A.
    Sharkey, Robert M.
    Govindan, Serengulam V.
    Goldenberg, David M.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
12345